There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
A new generation of novel cannabinoid compounds have been developed as marijuana substitutes
to avoid drug control laws and cannabinoid blood tests. 5F-MDMB-PINACA (also known
as 5F-ADB, 5F-ADB-PINACA), MDMB-CHIMICA, MDMB-FUBINACA, ADB-FUBINACA, and AMB-FUBINACA
(also known as FUB-AMB, MMB-FUBINACA) were tested for in vivo cannabinoid-like effects
to assess their abuse liability. Locomotor activity in mice was tested to screen for
locomotor depressant effects and to identify behaviorally-active dose ranges and times
of peak effect. Discriminative stimulus effects were tested in rats trained to discriminate
Δ 9 -tetrahydrocannabinol (3 mg/kg, 30-min pretreatment). 5F-MDMB-PINACA (ED 50 =1.1
mg/kg) and MDMB-CHIMICA (ED 50 =0.024 mg/kg) produced short-acting (30 min) depression
of locomotor activity. ADB-FUBINACA (ED 50 =0.19 mg/kg), and AMB-FUBINACA (ED 50 =0.19
mg/kg) depressed locomotor activity for 60–90 min; whereas MDMB-FUBINACA (ED 50 =0.04
mg/kg) depressed locomotor activity for 150 min. AMB-FUBINACA produced tremors at
the highest dose tested. 5F-MDMB-PINACA (ED 50 =0.07), MDMB-CHIMICA (ED 50 =0.01 mg/kg),
MDMB-FUBINACA (ED 50 =0.051 mg/kg), ADB-FUBINACA (ED 50 =0.075 mg/kg) and AMB-FUBINACA
(ED 50 =0.029) fully substituted for the discriminative stimulus effects of Δ 9 -THC
following 15-min pretreatment. All 5 compounds decreased locomotor activity and produced
discriminative stimulus effects similar to those of Δ 9 -THC, which suggests they
may have abuse liability similar to that of Δ 9 -THC. AMB-FUBINACA may have an increased
risk of toxicities in recreational users.